Printer Friendly

INAMED CORPORATION TO BUY BACK SHARES

 INAMED CORPORATION TO BUY BACK SHARES
 SANTA BARBARA, Calif., July 16 /PRNewswire/ -- INAMED Corporation


(NASDAQ: IMDC; PSE: INA), headquartered here, today announced that its board of directors had authorized the repurchase of up to 2 million shares of INAMED common stock through the next 12 months in open market or privately-negotiated transactions.
 INAMED currently has about 8.2 million common shares outstanding. The company's common stock price closed on July 15 at $2.875.
 The company said the decision to repurchase the company's outstanding shares was greatly due to the perceived undervaluation of the company's stock. INAMED reported net income of $1,007,374, or $.12 per share, on record sales of $16,731,906 for the first quarter ended March 31, 1992, as compared to the net income of $133,698, or $.02 per share, on sales of $9,650,500 in the first quarter of 1991.
 -0- 7/16/92
 /CONTACT: Donald K. McGhan, chairman, or Michael D. Farney, C.E.O. of INAMED, 805-684-6277; or Jimmy Caplan of Market Markers, 805-569-0076, for INAMED/
 (IMDC) CO: INAMED Corporation ST: Calfironia IN: MTC ST:


JP -- NYON1 -- 9891 07/16/92 09:15 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 16, 1992
Words:194
Previous Article:ZENITH REPORTS SECOND-QUARTER LOSS, RECORDS SIGNIFICANT ROYALTY INCOME
Next Article:RHONE-POULENC RORER SUB-LICENSES PENETREX(R) ANTIBIOTIC FROM WARNER-LAMBERT AND DAINIPPON FOR NORTH AMERICAN MARKET
Topics:


Related Articles
INAMED REPORTS THIRD QUARTER RESULTS
INAMED NAMES FARNEY CEO
INAMED REPORTS RECORD NINE MONTH SALES AND PROFITS
INAMED REPORTS RECORD SECOND QUARTER AND SIX MONTH PROFITS
INAMED ANNOUNCES SALE OF ONE SUBSIDIARY AND CHANGES IN MANUFACTURING AT ANOTHER
INAMED REPORTS RECORD THIRD QUARTER RESULTS
INAMED JOINS GLOBAL BREAST IMPLANT SETTLEMENT; COMPANY TO PAY $25 MILLION TO SETTLEMENT FUND
Inamed Corporation Licenses Rights for Product Applications From Advanced Tissue Sciences.
WR Hambrecht + Co Initiates Coverage of INAMED (Nasdaq: IMDC) With a Buy Rating and $30 Target.
BRIEFCASE SCENIC WILL LEAVE AIRPORT IN MARCH.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters